Exscientia PLC is a drug design and development company. The Company combines precision design with integrated experimentation to invent and develop drugs. It uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. It uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. It has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. It combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Company's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.

Employees

483

Sector

Biotechnology & Medical Research

More about the company

Market Closed - Nasdaq 04:00:00 2024-11-19 pm EST			5-day change	1st Jan Change
4.840 ^USD	+3.20%		-.--%	-

24-11-20	Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index	CI
24-11-20	Recursion Pharmaceuticals, Exscientia Complete Business Combination	MT

Market Cap	500M 669M 583M 550M 936M 64.17B 939M 6.58B 2.53B 32.64B 2.51B 2.46B 105B	P/E 2022	-4.55x	P/E 2023	-4.28x
Enterprise Value	156M 209M 182M 171M 292M 19.99B 293M 2.05B 787M 10.17B 782M 766M 32.72B	EV / Sales 2022	1.9x	EV / Sales 2023	14.2x
Free-Float	36.87%	Yield 2022 *	-	Yield 2023	-

24-11-20	Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index	CI
24-11-20	Recursion Pharmaceuticals, Exscientia Complete Business Combination	MT
24-11-20	Recursion Appoints Ben Taylor as Chief Financial Officer	CI
24-11-20	Recursion Announces Management Changes	CI
24-11-19	Recursion Pharmaceuticals, Inc. completed the acquisition of Exscientia plc.	CI
24-11-19	Exscientia plc(NasdaqGS:EXAI) dropped from NASDAQ Composite Index	CI
24-11-19	Exscientia plc(NasdaqGS:EXAI) dropped from NASDAQ Biotechnology Index	CI
24-11-13	Recursion Pharmaceuticals, Exscientia Shareholders Approve Proposed Combination	MT
24-11-08	Exscientia plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-10-16	Exscientia Expects $15 Million in Milestone Payments From Sanofi	MT
24-09-04	Exscientia plc Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 07:00 AM
24-08-15	Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024	CI
24-08-15	Exscientia plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

24-08-09	TD Cowen Downgrades Exscientia to Hold	MT
24-07-09	TD Cowen Initiates Exscientia at Buy	MT
23-10-17	Barclays Cuts Price Target on Exscientia to $10 From $12, Maintains Overweight Rating	MT
23-10-10	Morgan Stanley Cuts Exscientia Price Target to $7 From $14, Maintains Equal Weight Rating	MT
23-10-09	Berenberg Bank Adjusts Exscientia to $10 From $14, Maintains Buy Rating	MT

Exscientia plc Stock

Stocks

EXAI

US30223G1022

Biotechnology & Medical Research

Valuation: Exscientia plc

Latest news: Exscientia plc

Analysts' recommendations: Exscientia plc

Press Releases: Exscientia plc

News in other languages: Exscientia plc

Quotes and Performance

Price Extremes

Managers and Directors: Exscientia plc

Other Biotechnology & Medical Research

Financials

Company Profile

24-11-20	Exscientia : Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery Form 6 K	PU
24-11-20	Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery	AQ
24-11-13	Exscientia : Recursion and Exscientia Shareholders Approve the Proposed Combination Form 6 K	PU
24-11-08	Exscientia : Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive (Loss)/Income for the three and nine months ended September 30, 2024 and 2023 Form 6 K	PU
24-11-06	Exscientia : FIRST AMENDMENT TO TRANSACTION AGREEMENT Form 6 K	PU

24-10-16	Exscientia franchit des étapes importantes pour deux de ses programmes dans le cadre de sa collaboration avec Sanofi
24-10-16	Exscientia erreicht Meilensteine für zwei Programme im Rahmen der Zusammenarbeit mit Sanofi
24-10-09	Exscientia présentera de nouvelles données précliniques pour les inhibiteurs de la LSD1 et du MALT1 conçus par l'IA à l'ENA 2024
24-10-09	Exscientia präsentiert auf der ENA 2024 neue präklinische Daten für KI-gestützte LSD1- und MALT1-Inhibitoren
24-08-28	Exscientia wird auf der 22nd Annual Global Healthcare Conference Präsentation durchführen

Manager	Title	Age	Since
Marie-Louise Fjaellskog CTO	Chief Tech/Sci/R&D Officer	61	2024-06-05
Eileen Jennings-Brown CTO	Chief Tech/Sci/R&D Officer	-	2022-04-30
John Overington CTO	Chief Tech/Sci/R&D Officer	-	2024-04-30

Director	Title	Age	Since
Mario Polywka BRD	Director/Board Member	63	2017-09-27
Robert Ghenchev BRD	Director/Board Member	43	2020-04-30
Elizabeth Crain CHM	Chairman	61	2024-02-11

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXSCIENTIA PLC	+3.20%	-.--%	-.--%	-4.35%	633M
LONZA GROUP AG	+0.11%	+2.71%	+0.44%	+26.85%	46.28B
IQVIA HOLDINGS INC.	-1.12%	+1.78%	+42.30%	+27.55%	43.85B
REVOLUTION MEDICINES, INC.	-3.04%	-6.29%	+338.56%	+515.97%	40.93B
BEONE MEDICINES AG	-0.74%	+1.25%	+4.92%	+67.98%	39.89B
CELLTRION, INC.	-0.50%	+0.67%	+10.29%	+41.28%	29.5B
MEDPACE HOLDINGS, INC.	-0.46%	+4.22%	+22.81%	+139.44%	17.09B
ASCENDIS PHARMA A/S	-0.97%	-10.17%	-	-	15.55B
EUROFINS SCIENTIFIC SE	-0.57%	+8.12%	+22.19%	+38.68%	15.22B
TEMPUS AI, INC.	-3.14%	+31.91%	-11.79%	-	14.05B
Average	-0.72%	+3.39%	+47.75%	+106.68%	26.3B
Weighted average by Cap.	-1.09%	+1.87%	+67.87%	+130.54%

	2022	2023
Net sales	27.22M 36.46M 31.74M 29.97M 50.98M 3.5B 51.16M 358M 138M 1.78B 137M 134M 5.72B	20.08M 26.89M 23.41M 22.1M 37.6M 2.58B 37.74M 264M 102M 1.31B 101M 98.73M 4.22B
Net income	-119M -159M -138M -131M -222M -15.24B -223M -1.56B -600M -7.75B -597M -584M -24.95B	-146M -195M -170M -161M -273M -18.74B -274M -1.92B -738M -9.53B -733M -718M -30.67B
Net Debt	-492M -659M -574M -542M -921M -63.16B -924M -6.47B -2.49B -32.13B -2.47B -2.42B -103B	-344M -461M -401M -379M -644M -44.18B -647M -4.53B -1.74B -22.47B -1.73B -1.69B -72.31B

3 years	3.8	7.91
5 years	3.8	30.38
10 years	3.8	30.38